ClinicalTrials.gg
CompletedNCT02476968ORZORAUpdated Sep 10, 2022Results posted

To Assess the Efficacy and Safety of Olaparib Maintenance Monotherapy in the Treatment of Ovarian Cancer

A Phase 4 interventional study of Olaparib in BRCA or HRR+ Mutated Ovarian Cancer Patients, sponsored by AstraZeneca. Completed at 58 sites in 8 countries. Open to female participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2022-09-10.

Sponsored by AstraZeneca · Phase 4, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
181
Allocation
Non-randomized
Ages
18 Years to 130 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 69 studies testing olaparib in Ovarian Neoplasms — 13 open to participants now, 26 under way, 9 of them phase 3. olaparib · Ovarian Neoplasms.

Enrollment
24th of 69
181 · median 97
Started
2015
with 3 others
Phase 4
3 of 69
1 open now
Registered
21st of 69
by date
Lead sponsor
21 of 69
AstraZeneca

Among the 69 studies testing olaparib in Ovarian Neoplasms, this one is the 24th largest by enrollment, is one of 4 that started in 2015, is one of 3 in phase 4, and was the 21st registered.

Ovarian Neoplasms

3,387 studies on the registry are indexed under Ovarian Neoplasms; 791 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

13 of the 69 studies testing olaparib in Ovarian Neoplasms are open now, in 8 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 13 open studies →

About olaparib

olaparib: first FDA approval 2014 (LYNPARZA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 602 Ovarian Neoplasms studies recruiting now, 439 (73%) set no upper age limit and 107 (18%) stop at 75 or younger; 39 take children under 18; 45 take healthy volunteers.

This study: 18 Years to 130 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 69 studies testing olaparib in Ovarian Neoplasms, or all of them as a file.
02

Study summary

This is a prospective, open-label, single arm, multi-center study to assess the real world clinical effectiveness and safety of olaparib maintenance monotherapy as the capsule formulation (in line with the EU approved prescribing information) and will be conducted in platinum-sensitive relapsed high grade epithelial ovarian cancer patients (including patients with primary peritoneal and / or fallopian tube cancer) who carry germline or somatic BRCA mutations (documented mutation in BRCA1 or BRCA2 that is predicted to be deleterious or suspected deleterious [known or predicted to be detrimental/lead to loss of function]).

Read the detailed description

The study will recruit approximately 250 patients with sBRCAm disease or gBRCAm disease, with the aim to accrue a minimum of 50 patients with sBRCAm disease.

Patients with an unknown germline BRCA mutated status or gBRCAwt disease or previously identified as having a BRCAm disease by a tumour test will be considered for screening and will undergo, upon informed consent signature, central tumor and blood testing to determine their BRCA mutation status. In addition to central BRCA testing, patients screened for the study with unknown BRCA status or with known gBRCAwt status, for whom an adequate archival tumour tissue sample is available, will be tested for qualifying HRR gene alterations. Patients confirmed to carry a deleterious or suspected deleterious BRCA-independent genetic alteration in any of 13 genes involved in the Homologous Recombination Repair (HRR) pathway (HRRm cohort) will be allowed into an additional exploratory cohort (HRRm cohort). It is expected that approximately 25 patients will be included in the HRRm cohort before the target number of 250 patients with BRCAm disease is reached.

Patients will be assigned olaparib capsules orally 400 mg twice daily. They should initiate olaparib treatment within 8 weeks after their last dose of platinum-containing chemotherapy (last dose is the day of the last infusion) and will be assessed every 4 weeks whilst on treatment.

All patients will have clinical and objective radiological tumour assessments according to modified Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 guidelines at baseline and every 12 weeks relative to date of enrolment, until objective radiological disease progression as determined by the investigator. Patients could continue to receive olaparib for as long as determined by the investigator, until objective radiological disease progression or as long as in the investigator's opinion they are benefiting from treatment in relation to other clinical assessments and they do not meet any other discontinuation criteria. Once a patient has discontinued olaparib she will be managed as per local clinical practice but will remain in the study and data will be collected on subsequent treatments, progression, overall survival and safety.

For exploratory analysis purposes, patients will be asked to provide consent to:

  1. Optional tumour samples at baseline and at disease progression
  2. An optional blood sample only for patients with a confirmed sBRCAm or HRRm disease
03

Conditions studied

  • BRCA or HRR+ Mutated Ovarian Cancer Patients

Browse trials for

04

Who can participate

Ages eligible
18 Years to 130 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Provision of prior to any study specific procedures
  2. Age 18 years or over
  3. Documented germline or somatic mutation in BRCA1 or BRCA2 genes that is predicted to be deleterious or suspected deleterious (known or predicted to be detrimental/lead to loss of function) [Genetic counselling for patients with germline BRCA mutations should be performed according to local regulations] Or Tumour BRCAwt status and documented qualifying mutation in any of 13 genes involved in the HRR pathway, excluding BRCA1 and BRCA2 (ATM, BARD1, BRIP1,CDK12, CHEK1, CHEK2, FANCL, PALB2, PPP2R2A, RAD51B, RAD51C, RAD51D,and RAD54L), identified by the Lynparza HRR Assay in (i.e.,BRCA-independent HRRm)
  4. Patients with platinum sensitive high grade epithelial ovarian cancers (including primary peritoneal and/or fallopian tube cancer):

    • Platinum sensitive disease is defined as disease progression ≥6 months after completion of their last dose of platinum based chemotherapy
  5. Patients should have received at least 2 previous lines of platinum containing therapy prior to enrolment:

    • For the last chemotherapy course immediately prior to enrolment on the study, patients must be, in the opinion of the investigator, in response (partial or complete radiological response) and no evidence of a rising CA-125, following completion of this chemotherapy course.
  6. Patients must have normal organ and bone marrow function measured within 28 days of enrolment, as defined below:

    • ≥ 10.0 g/dL with no blood transfusions in the past 28 days
    • (ANC) ≥ 1.5 x 109/L
    • count ≥ 100 x 109/L
  7. Total ≤ 1.5 x institutional (ULN), (AST) (Serum Glutamic Oxaloacetic Transaminase [SGOT]) / Alanine aminotransferase (ALT) (Serum Glutamic Pyruvate Transaminase [SGPT]) ≤ 2.5 x institutional ULN unless liver are present in which case they must be ≤ 5x ULN
  8. > 50 ml/min (calculated)
  9. Patients must be or have evidence of non-childbearing status for women of .

Postmenopausal is defined as any of the following:

  • Amenorrhoea for 1 year or more following cessation of exogenous hormonal treatments
  • For women under 50 years old, luteinizing hormone (LH) and follicle stimulating hormone (FSH) levels in the post-menopausal range
  • Radiation-induced oophorectomy, with interval of 1 year or more since last menses
  • Chemotherapy-induced menopause, with interval of 1 year or more since last menses
  • Surgical sterilisation (bilateral oophorectomy or hysterectomy).

Exclusion criteria

Exclusion Criteria:

  1. Patients previously diagnosed with gBRCAm disease
  2. Participation in another clinical study with an product during the most recent chemotherapy course
  3. Patients with a known to olaparib or any of the of the product
  4. Patients receiving any systemic chemotherapy or radiotherapy (except for palliative reasons) or major surgery within 3 weeks prior to olaparib treatment. Major surgery within 3 weeks of starting study treatment and patients must have recovered from any effects of any major surgery
  5. Persistent toxicities Common Terminology Criteria for Adverse Event () grade 2 caused by previous cancer therapy, excluding alopecia
  6. Patients with myelodysplastic syndrome/acute myeloid leukaemia
  7. Immuno-compromised patients e.g., (HIV) requiring treatment or active or C
  8. Patients with symptomatic uncontrolled . The patient can receive a stable dose of before and during the study as long as these were started at least 4 weeks prior to treatment. Patients with spinal cord compression unless considered to have received definitive treatment for this and evidence of clinically stable disease (SD) for 28 days
  9. Patients considered to be at a high medical risk due to a serious, uncontrolled medical disorder, systemic disease or active, uncontrolled infection
  10. Currently pregnant (confirmed with a positive pregnancy test) or breastfeeding.
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 4
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
181 participants (actual)

Study arms

  • Other
    Olaparib

    Open Label Drug

    Drug: Olaparib

Interventions

  • Olaparib Capsule - 50 mg. Olaparib capsules will be packed in high-density polyethylene (HDPE) bottles with child-resistant closures. Each bottle will contain 120 capsules and 4 bottles will be dispensed for a 4 weekly visit, with a 2 day overage. Patients will be administered olaparib capsules orally at a dose of 400 mg twice daily. Eight 50 mg olaparib capsules should be taken at the same time each day approximately 12 hours apart with approximately 240 mL of water.

    Also known as: Lynparza

06

What researchers measure

Primary outcomes

  1. Progression-Free Survival (PFS)

    To assess the real-world clinical effectiveness of olaparib maintenance monotherapy in patients with BRCAm and sBRCAm ovarian cancer by assessment of PFS. The PFS was defined as the time from the date of enrolment until date of objective radiological disease progression (assessed by the Investigator via Response Evaluation Criteria in Solid Tumors, version 1.1 \[RECIST 1.1\]), or death (by any cause in absence of disease progression) regardless of whether the patient withdrew from therapy or received another anti-cancer therapy prior to disease progression. Objective progression was defined as at least a 20% increase in the sum of the diameters of the target lesions (compared to previous minimum sum) and an absolute increase of \> 5 millimeters, or an overall non-target lesion assessment of progression or a new lesion. The data cut-off (DCO) for the primary analysis of the study occurred after approximately 60% maturity of PFS in the sBRCAm and all BRCAm patient populations.

    Time frame: Tumour assessments at baseline then every 12 weeks relative to date of enrolment until RECIST 1.1-defined progression. Assessed until primary analysis DCO of 17 April 2020 (up to maximum of 55 months).

Secondary outcomes

  1. Overall Survival (OS); Assessed at Primary Analysis

    To assess the real-world clinical effectiveness of olaparib maintenance monotherapy in patients with BRCAm and sBRCAm ovarian cancer by assessment of OS. The OS was defined as the time from the date of enrolment until death due to any cause regardless of whether the patient withdrew from therapy or received another anti-cancer therapy. Any patient not known to have died at the time of analysis was censored based on the last recorded date on which the patient was known to be alive. Pre-specified analysis of OS was performed at the time of primary analysis of PFS; a further analysis of OS was performed after approximately 60% maturity of OS in the sBRCAm and all BRCAm patient populations (and reported as a separate outcome measure).

    Time frame: From baseline until death due to any cause. Assessed until primary analysis DCO of 17 April 2020 (up to maximum of 55 months).

  2. Time to Second Progression (PFS2) or Death; Assessed at Primary Analysis

    To assess the real-world clinical effectiveness of olaparib maintenance monotherapy in patients with BRCAm and sBRCAm ovarian cancer by assessment of PFS2. The PFS2 was defined as the time from the date of enrolment to the earliest progression event subsequent to that used for the primary variable PFS or death (by any cause) in the absence of progression. Patients whose progression event for PFS was death had this counted as a progression event for PFS2 also. The date of second progression was recorded by the Investigator and defined according to local standard clinical practice and could involve any of the following: objective radiological, symptomatic, cancer antigen-125 (CA-125) progression or death. Pre-specified analysis of PFS2 was performed at the time of the primary analysis; a further analysis of PFS2 was performed at the final analysis (and reported as a separate outcome measure).

    Time frame: Tumour assessments (and blood samples for CA-125, if applicable) at baseline then every 12 weeks relative to date of enrolment until second progression. Assessed until primary analysis DCO of 17 April 2020 (up to maximum of 55 months).

  3. Time to First Subsequent Therapy (Treatment) or Death (TFST); Assessed at Primary Analysis

    To assess the real-world clinical effectiveness of olaparib maintenance monotherapy in patients with BRCAm and sBRCAm ovarian cancer by assessment of TFST. The TFST was defined as the time from the date of enrolment to the earlier of first subsequent anti-cancer therapy start date (excluding radiotherapy), or death date. Pre-specified analysis of TFST was performed at the time of the primary analysis; a further analysis of TFST was performed at the final analysis (and reported as a separate outcome measure).

    Time frame: From enrolment to first subsequent therapy or death. Assessed every 12 weeks following treatment discontinuation. Assessed until primary analysis DCO of 17 April 2020 (up to maximum of 55 months).

  4. Time to Second Subsequent Therapy (Treatment) or Death (TSST); Assessed at Primary Analysis

    To assess the real-world clinical effectiveness of olaparib maintenance monotherapy in patients with BRCAm and sBRCAm ovarian cancer by assessment of TSST. The TSST was defined as the time from the date of enrolment to the earlier of the date of second subsequent anti-cancer therapy start date, or death date. Pre-specified analysis of TSST was performed at the time of the primary analysis; a further analysis of TSST was performed at the final analysis (and reported as a separate outcome measure).

    Time frame: From enrolment to second subsequent therapy or death. Assessed every 12 weeks following treatment discontinuation. Assessed until primary analysis DCO of 17 April 2020 (up to maximum of 55 months).

  5. Time to Discontinuation of Treatment or Death (TDT)

    To assess the real-world clinical effectiveness of olaparib maintenance monotherapy in patients with BRCAm and sBRCAm ovarian cancer by assessment of TDT. The TDT was defined as the time from the date of enrolment to the earlier of the date of study treatment discontinuation or death.

    Time frame: From enrolment to study treatment discontinuation or death (up to maximum of 6 years).

  6. Change From Baseline in Functional Assessment of Cancer Therapy - Ovarian (FACT-O) Trial Outcome Index (TOI) Scores Over Time

    To assess the Quality of Life (QoL) of patients with BRCAm and sBRCAm ovarian cancer by evaluation of FACT-O TOI. The TOI score was derived from the sum of the scores of the 25 items included in the physical well-being (7 items), functional well-being (7 items), and additional concerns ovarian cancer subscale (11 items) of the FACT-O questionnaire version 4. The FACT-O TOI score ranges from 0-100, with a higher score indicating better QoL. A change (increase or decrease) in score of at least 10 points from baseline was defined as clinically meaningful. A positive change in score from baseline indicates an improvement.

    Time frame: QoL questionnaires at baseline, Day 29 (Week 4), then every 12 weeks for 24 months or DCO for primary analysis, whichever came first. QoL questionnaires also collected at discontinuation of study treatment visit and 30 days post last dose.

  7. Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Total Scores Over Time

    To assess the QoL of patients with BRCAm and sBRCAm ovarian cancer by evaluation of FACIT-F. The FACIT-F is a 13-item questionnaire to assess patients' fatigue experience and its impact on their daily lives over the past 7 days. The FACIT-F total score ranges from 0-52, with a higher score indicating a lower level of fatigue (and better QoL). Changes in scores of ≥3 points were defined to be clinically meaningful. A positive change in score from baseline indicates an improvement.

    Time frame: QoL questionnaires at baseline, Day 29 (Week 4), then every 12 weeks for 24 months or DCO for primary analysis, whichever came first. QoL questionnaires also collected at discontinuation of study treatment visit and 30 days post last dose.

  8. Change From Baseline in Functional Living Index-Emesis (FLIE) Questionnaire Total Scores Over Time

    The FLIE captures the impact of nausea and vomiting on patient's QoL. The FLIE consists of 18 items (9 nausea-specific and 9 vomiting-specific items), rated from 1 to 7. Two domain scores and a total score are derived; the total score ranges 18-126 and a higher score indicates a lower impact (and better QoL). A positive change in score from baseline indicates an improvement.

    Time frame: FLIE questionnaires at baseline, weekly until Day 29 (Week 4), then every 12 weeks for 24 months or DCO for primary analysis, whichever came first. FLIE questionnaires also collected at discontinuation of study treatment visit and 30 days post last dose.

  9. OS; Assessed at Final Analysis

    To assess the real-world clinical effectiveness of olaparib maintenance monotherapy in patients with BRCAm and sBRCAm ovarian cancer by assessment of OS. The OS was defined as the time from the date of enrolment until death due to any cause regardless of whether the patient withdrew from therapy or received another anti-cancer therapy. Any patient not known to have died at the time of analysis was censored based on the last recorded date on which the patient was known to be alive.

    Time frame: From baseline until death due to any cause (up to maximum of 6 years).

  10. PFS2 or Death; Assessed at Final Analysis

    To assess the real-world clinical effectiveness of olaparib maintenance monotherapy in patients with BRCAm and sBRCAm ovarian cancer by assessment of PFS2. The PFS2 was defined as the time from the date of enrolment to the earliest progression event subsequent to that used for the primary variable PFS or death (by any cause) in the absence of progression. Patients whose progression event for PFS was death had this counted as a progression event for PFS2 also. The date of second progression was recorded by the Investigator and defined according to local standard clinical practice and could involve any of the following: objective radiological, symptomatic, CA-125 progression or death.

    Time frame: Tumour assessments (and blood samples for CA-125, if applicable) at baseline then every 12 weeks relative to date of enrolment until second progression (up to maximum of 6 years).

  11. TFST; Assessed at Final Analysis

    To assess the real-world clinical effectiveness of olaparib maintenance monotherapy in patients with BRCAm and sBRCAm ovarian cancer by assessment of TFST. The TFST was defined as the time from the date of enrolment to the earlier of first subsequent anti-cancer therapy start date (excluding radiotherapy), or death date.

    Time frame: From enrolment to first subsequent therapy or death. Assessed every 12 weeks following treatment discontinuation (up to maximum of 6 years).

  12. TSST; Assessed at Final Analysis

    To assess the real-world clinical effectiveness of olaparib maintenance monotherapy in patients with BRCAm and sBRCAm ovarian cancer by assessment of TSST. The TSST was defined as the time from the date of enrolment to the earlier of the date of second subsequent anti-cancer therapy start date, or death date.

    Time frame: From enrolment to second subsequent therapy or death. Assessed every 12 weeks following treatment discontinuation (up to maximum of 6 years).

07

Results

Posted Jun 18, 2021

Participant flow

This study was conducted in 8 countries in patients with platinum sensitive relapsed high grade epithelial ovarian (including fallopian tube or primary peritoneal) cancer, who were in complete or partial response to platinum-based chemotherapy.

Participant flow — Overall Study
MilestoneOverall BRCAmHRRm^Unassigned (Not BRCAm, Not HRRm^)
Started145333
Received treatment143322
Completed50150
Not completed95183
Withdrew: Other020
Withdrew: Lost to follow-up1001
Withdrew: Death4881
Withdrew: Eligibility criteria not fulfilled001
Withdrew: Patient decision3780

Outcome measures

PrimaryProgression-Free Survival (PFS)

To assess the real-world clinical effectiveness of olaparib maintenance monotherapy in patients with BRCAm and sBRCAm ovarian cancer by assessment of PFS. The PFS was defined as the time from the date of enrolment until date of objective radiological disease progression (assessed by the Investigator via Response Evaluation Criteria in Solid Tumors, version 1.1 \[RECIST 1.1\]), or death (by any cause in absence of disease progression) regardless of whether the patient withdrew from therapy or received another anti-cancer therapy prior to disease progression. Objective progression was defined as at least a 20% increase in the sum of the diameters of the target lesions (compared to previous minimum sum) and an absolute increase of \> 5 millimeters, or an overall non-target lesion assessment of progression or a new lesion. The data cut-off (DCO) for the primary analysis of the study occurred after approximately 60% maturity of PFS in the sBRCAm and all BRCAm patient populations.

Time frame:
Tumour assessments at baseline then every 12 weeks relative to date of enrolment until RECIST 1.1-defined progression. Assessed until primary analysis DCO of 17 April 2020 (up to maximum of 55 months).
Reported as:
Median · months
Progression-Free Survival (PFS)
monthsOverall BRCAmsBRCAm
Progression-Free Survival (PFS)18.0 (14.3 to 22.1)16.6 (12.4 to 22.2)
SecondaryOverall Survival (OS); Assessed at Primary Analysis

To assess the real-world clinical effectiveness of olaparib maintenance monotherapy in patients with BRCAm and sBRCAm ovarian cancer by assessment of OS. The OS was defined as the time from the date of enrolment until death due to any cause regardless of whether the patient withdrew from therapy or received another anti-cancer therapy. Any patient not known to have died at the time of analysis was censored based on the last recorded date on which the patient was known to be alive. Pre-specified analysis of OS was performed at the time of primary analysis of PFS; a further analysis of OS was performed after approximately 60% maturity of OS in the sBRCAm and all BRCAm patient populations (and reported as a separate outcome measure).

Time frame:
From baseline until death due to any cause. Assessed until primary analysis DCO of 17 April 2020 (up to maximum of 55 months).
Reported as:
Median · months
Overall Survival (OS); Assessed at Primary Analysis
monthsOverall BRCAmsBRCAm
Overall Survival (OS); Assessed at Primary Analysis47.6 (36.1 to NA)NA (33.2 to NA)
SecondaryTime to Second Progression (PFS2) or Death; Assessed at Primary Analysis

To assess the real-world clinical effectiveness of olaparib maintenance monotherapy in patients with BRCAm and sBRCAm ovarian cancer by assessment of PFS2. The PFS2 was defined as the time from the date of enrolment to the earliest progression event subsequent to that used for the primary variable PFS or death (by any cause) in the absence of progression. Patients whose progression event for PFS was death had this counted as a progression event for PFS2 also. The date of second progression was recorded by the Investigator and defined according to local standard clinical practice and could involve any of the following: objective radiological, symptomatic, cancer antigen-125 (CA-125) progression or death. Pre-specified analysis of PFS2 was performed at the time of the primary analysis; a further analysis of PFS2 was performed at the final analysis (and reported as a separate outcome measure).

Time frame:
Tumour assessments (and blood samples for CA-125, if applicable) at baseline then every 12 weeks relative to date of enrolment until second progression. Assessed until primary analysis DCO of 17 April 2020 (up to maximum of 55 months).
Reported as:
Median · months
Time to Second Progression (PFS2) or Death; Assessed at Primary Analysis
monthsOverall BRCAmsBRCAm
Time to Second Progression (PFS2) or Death; Assessed at Primary Analysis30.9 (24.7 to 40.0)24.7 (21.8 to 36.1)
SecondaryTime to First Subsequent Therapy (Treatment) or Death (TFST); Assessed at Primary Analysis

To assess the real-world clinical effectiveness of olaparib maintenance monotherapy in patients with BRCAm and sBRCAm ovarian cancer by assessment of TFST. The TFST was defined as the time from the date of enrolment to the earlier of first subsequent anti-cancer therapy start date (excluding radiotherapy), or death date. Pre-specified analysis of TFST was performed at the time of the primary analysis; a further analysis of TFST was performed at the final analysis (and reported as a separate outcome measure).

Time frame:
From enrolment to first subsequent therapy or death. Assessed every 12 weeks following treatment discontinuation. Assessed until primary analysis DCO of 17 April 2020 (up to maximum of 55 months).
Reported as:
Median · months
Time to First Subsequent Therapy (Treatment) or Death (TFST); Assessed at Primary Analysis
monthsOverall BRCAmsBRCAm
Time to First Subsequent Therapy (Treatment) or Death (TFST); Assessed at Primary Analysis37.6 (23.5 to 47.6)31.5 (19.5 to NA)
SecondaryTime to Second Subsequent Therapy (Treatment) or Death (TSST); Assessed at Primary Analysis

To assess the real-world clinical effectiveness of olaparib maintenance monotherapy in patients with BRCAm and sBRCAm ovarian cancer by assessment of TSST. The TSST was defined as the time from the date of enrolment to the earlier of the date of second subsequent anti-cancer therapy start date, or death date. Pre-specified analysis of TSST was performed at the time of the primary analysis; a further analysis of TSST was performed at the final analysis (and reported as a separate outcome measure).

Time frame:
From enrolment to second subsequent therapy or death. Assessed every 12 weeks following treatment discontinuation. Assessed until primary analysis DCO of 17 April 2020 (up to maximum of 55 months).
Reported as:
Median · months
Time to Second Subsequent Therapy (Treatment) or Death (TSST); Assessed at Primary Analysis
monthsOverall BRCAmsBRCAm
Time to Second Subsequent Therapy (Treatment) or Death (TSST); Assessed at Primary Analysis47.6 (29.4 to NA)NA (24.7 to NA)
SecondaryTime to Discontinuation of Treatment or Death (TDT)

To assess the real-world clinical effectiveness of olaparib maintenance monotherapy in patients with BRCAm and sBRCAm ovarian cancer by assessment of TDT. The TDT was defined as the time from the date of enrolment to the earlier of the date of study treatment discontinuation or death.

Time frame:
From enrolment to study treatment discontinuation or death (up to maximum of 6 years).
Reported as:
Median · months
Time to Discontinuation of Treatment or Death (TDT)
monthsOverall BRCAmsBRCAm
Time to Discontinuation of Treatment or Death (TDT)19.8 (14.3 to 22.9)19.0 (13.5 to 22.8)
SecondaryChange From Baseline in Functional Assessment of Cancer Therapy - Ovarian (FACT-O) Trial Outcome Index (TOI) Scores Over Time

To assess the Quality of Life (QoL) of patients with BRCAm and sBRCAm ovarian cancer by evaluation of FACT-O TOI. The TOI score was derived from the sum of the scores of the 25 items included in the physical well-being (7 items), functional well-being (7 items), and additional concerns ovarian cancer subscale (11 items) of the FACT-O questionnaire version 4. The FACT-O TOI score ranges from 0-100, with a higher score indicating better QoL. A change (increase or decrease) in score of at least 10 points from baseline was defined as clinically meaningful. A positive change in score from baseline indicates an improvement.

Time frame:
QoL questionnaires at baseline, Day 29 (Week 4), then every 12 weeks for 24 months or DCO for primary analysis, whichever came first. QoL questionnaires also collected at discontinuation of study treatment visit and 30 days post last dose.
Reported as:
Mean · scores on a scale
Change From Baseline in Functional Assessment of Cancer Therapy - Ovarian (FACT-O) Trial Outcome Index (TOI) Scores Over Time
scores on a scaleOverall BRCAmsBRCAm
Week 4-2.2 ± 9.82-1.9 ± 9.59
Week 16-1.3 ± 10.04-0.3 ± 10.85
Week 281.2 ± 9.443.2 ± 10.25
Week 401.6 ± 10.724.1 ± 10.48
Week 523.2 ± 9.034.9 ± 7.84
Week 641.8 ± 9.880.8 ± 9.72
Week 761.4 ± 9.270.3 ± 9.83
Week 882.0 ± 9.971.5 ± 10.86
Week 100-0.2 ± 9.41-3.5 ± 7.54
Discontinuation of olaparib visit-4.7 ± 13.00-7.4 ± 15.53
30 days post discontinuation-8.0 ± 13.45-4.3 ± 13.36
SecondaryChange From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Total Scores Over Time

To assess the QoL of patients with BRCAm and sBRCAm ovarian cancer by evaluation of FACIT-F. The FACIT-F is a 13-item questionnaire to assess patients' fatigue experience and its impact on their daily lives over the past 7 days. The FACIT-F total score ranges from 0-52, with a higher score indicating a lower level of fatigue (and better QoL). Changes in scores of ≥3 points were defined to be clinically meaningful. A positive change in score from baseline indicates an improvement.

Time frame:
QoL questionnaires at baseline, Day 29 (Week 4), then every 12 weeks for 24 months or DCO for primary analysis, whichever came first. QoL questionnaires also collected at discontinuation of study treatment visit and 30 days post last dose.
Reported as:
Mean · scores on a scale
Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Total Scores Over Time
scores on a scaleOverall BRCAmsBRCAm
Week 4-2.9 ± 8.21-2.9 ± 7.58
Week 16-2.5 ± 7.54-2.7 ± 9.26
Week 28-1.2 ± 7.95-0.6 ± 7.25
Week 40-0.3 ± 7.910.9 ± 7.02
Week 520.6 ± 7.431.3 ± 7.25
Week 640.8 ± 7.260.5 ± 8.47
Week 76-0.3 ± 8.57-1.1 ± 8.74
Week 880.3 ± 8.45-0.9 ± 5.81
Week 100-0.4 ± 8.59-1.3 ± 8.75
Discontinuation of olaparib visit-2.3 ± 9.01-2.7 ± 9.32
30 days post discontinuation-5.2 ± 11.16-3.8 ± 9.65
SecondaryChange From Baseline in Functional Living Index-Emesis (FLIE) Questionnaire Total Scores Over Time

The FLIE captures the impact of nausea and vomiting on patient's QoL. The FLIE consists of 18 items (9 nausea-specific and 9 vomiting-specific items), rated from 1 to 7. Two domain scores and a total score are derived; the total score ranges 18-126 and a higher score indicates a lower impact (and better QoL). A positive change in score from baseline indicates an improvement.

Time frame:
FLIE questionnaires at baseline, weekly until Day 29 (Week 4), then every 12 weeks for 24 months or DCO for primary analysis, whichever came first. FLIE questionnaires also collected at discontinuation of study treatment visit and 30 days post last dose.
Reported as:
Mean · scores on a scale
Change From Baseline in Functional Living Index-Emesis (FLIE) Questionnaire Total Scores Over Time
scores on a scaleOverall BRCAmsBRCAm
Week 1-6.1 ± 18.62-1.6 ± 18.28
Week 2-4.5 ± 18.40-2.6 ± 15.97
Week 3-4.1 ± 14.57-3.9 ± 13.23
Week 4-4.8 ± 18.48-5.4 ± 19.92
Week 16-2.3 ± 11.50-6.3 ± 11.00
Week 28-1.6 ± 13.87-3.0 ± 7.94
Week 40-0.1 ± 14.07-3.2 ± 14.56
Week 520.9 ± 14.41-1.9 ± 11.64
Week 64-0.2 ± 15.93-1.0 ± 20.77
Week 760.9 ± 14.140.6 ± 6.60
Week 882.2 ± 10.04-1.3 ± 9.29
Week 1000.4 ± 10.370.1 ± 13.19
Discontinuation of olaparib visit-0.7 ± 20.17-8.8 ± 21.57
30 days post discontinuation-5.2 ± 17.02-5.6 ± 15.69
SecondaryOS; Assessed at Final Analysis

To assess the real-world clinical effectiveness of olaparib maintenance monotherapy in patients with BRCAm and sBRCAm ovarian cancer by assessment of OS. The OS was defined as the time from the date of enrolment until death due to any cause regardless of whether the patient withdrew from therapy or received another anti-cancer therapy. Any patient not known to have died at the time of analysis was censored based on the last recorded date on which the patient was known to be alive.

Time frame:
From baseline until death due to any cause (up to maximum of 6 years).
Reported as:
Median · months
OS; Assessed at Final Analysis
monthsOverall BRCAmsBRCAm
OS; Assessed at Final Analysis46.8 (37.9 to 54.4)43.2 (31.7 to NA)
SecondaryPFS2 or Death; Assessed at Final Analysis

To assess the real-world clinical effectiveness of olaparib maintenance monotherapy in patients with BRCAm and sBRCAm ovarian cancer by assessment of PFS2. The PFS2 was defined as the time from the date of enrolment to the earliest progression event subsequent to that used for the primary variable PFS or death (by any cause) in the absence of progression. Patients whose progression event for PFS was death had this counted as a progression event for PFS2 also. The date of second progression was recorded by the Investigator and defined according to local standard clinical practice and could involve any of the following: objective radiological, symptomatic, CA-125 progression or death.

Time frame:
Tumour assessments (and blood samples for CA-125, if applicable) at baseline then every 12 weeks relative to date of enrolment until second progression (up to maximum of 6 years).
Reported as:
Median · months
PFS2 or Death; Assessed at Final Analysis
monthsOverall BRCAmsBRCAm
PFS2 or Death; Assessed at Final Analysis34.0 (29.3 to 44.2)29.3 (23.7 to 44.2)
SecondaryTFST; Assessed at Final Analysis

To assess the real-world clinical effectiveness of olaparib maintenance monotherapy in patients with BRCAm and sBRCAm ovarian cancer by assessment of TFST. The TFST was defined as the time from the date of enrolment to the earlier of first subsequent anti-cancer therapy start date (excluding radiotherapy), or death date.

Time frame:
From enrolment to first subsequent therapy or death. Assessed every 12 weeks following treatment discontinuation (up to maximum of 6 years).
Reported as:
Median · months
TFST; Assessed at Final Analysis
monthsOverall BRCAmsBRCAm
TFST; Assessed at Final Analysis32.1 (25.8 to 40.0)31.7 (18.0 to NA)
SecondaryTSST; Assessed at Final Analysis

To assess the real-world clinical effectiveness of olaparib maintenance monotherapy in patients with BRCAm and sBRCAm ovarian cancer by assessment of TSST. The TSST was defined as the time from the date of enrolment to the earlier of the date of second subsequent anti-cancer therapy start date, or death date.

Time frame:
From enrolment to second subsequent therapy or death. Assessed every 12 weeks following treatment discontinuation (up to maximum of 6 years).
Reported as:
Median · months
TSST; Assessed at Final Analysis
monthsOverall BRCAmsBRCAm
TSST; Assessed at Final Analysis38.4 (31.5 to NA)32.1 (25.8 to 44.7)

Adverse events

Collected over From first dose of olaparib up to and including 30 days following the date of discontinuation of olaparib. Maximum timeframe of approximately 6 years.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
gBRCAm40/87 (46%)27/87 (31%)79/87 (90.8%)
sBRCAm28/55 (50.9%)13/55 (23.6%)51/55 (92.7%)
Overall BRCAm68/145 (46.9%)40/143 (28%)131/143 (91.6%)
HRRm14/33 (42.4%)7/32 (21.9%)29/32 (90.6%)
Unassigned (Not BRCAm, Not HRRm^)2/3 (66.7%)1/2 (50%)1/2 (50%)
Most frequent serious events
Showing 10 of 38
Most frequent serious events
EventgBRCAmsBRCAmOverall BRCAmHRRmUnassigned (Not BRCAm, Not HRRm^)
Small intestinal obstructionGastrointestinal disorders0/871/551/1430/321/2
AnaemiaBlood and lymphatic system disorders7/875/5512/1431/320/2
Urinary tract infectionInfections and infestations3/870/553/1431/320/2
Pulmonary embolismRespiratory, thoracic and mediastinal disorders3/870/553/1431/320/2
ThrombocytopeniaBlood and lymphatic system disorders0/870/550/1431/320/2
Myocardial infarctionCardiac disorders0/870/550/1431/320/2
Femoral neck fractureInjury, poisoning and procedural complications0/871/551/1431/320/2
Pleural effusionRespiratory, thoracic and mediastinal disorders0/870/550/1431/320/2
VertigoEar and labyrinth disorders0/870/550/1431/320/2
Gastroenteritis viralInfections and infestations0/870/550/1431/320/2
Most frequent other events
Showing 10 of 62
Most frequent other events
EventgBRCAmsBRCAmOverall BRCAmHRRmUnassigned (Not BRCAm, Not HRRm^)
NauseaGastrointestinal disorders49/8728/5578/14319/320/2
AnaemiaBlood and lymphatic system disorders38/8719/5557/14311/321/2
Gastrooesophageal reflux diseaseGastrointestinal disorders3/870/553/1432/321/2
VomitingGastrointestinal disorders24/8714/5538/14310/321/2
FatigueGeneral disorders38/8722/5560/14315/321/2
Foot fractureInjury, poisoning and procedural complications0/870/550/1430/321/2
Neutrophil count decreasedInvestigations5/872/557/1431/321/2
IrritabilityPsychiatric disorders0/870/550/1430/321/2
Taste disorderNervous system disorders0/870/550/1430/321/2
Personality changePsychiatric disorders0/870/550/1430/321/2

Baseline characteristics

All patients in the FAS (enrolled and assigned olaparib) were included in the baseline analysis. Where a patient did not meet all the eligibility criteria but was enrolled in error, they were still a part of the FAS.

Age, Continuous
Age, Continuous(years)Overall BRCAmHRRm^Unassigned (Not BRCAm, Not HRRm^)Total
Mean60.1 ± 10.7562.2 ± 9.7458.7 ± 9.0760.5 ± 10.52
Age, Customized
Age, Customized(Participants)Overall BRCAmHRRm^Unassigned (Not BRCAm, Not HRRm^)Total
<35 years0000
≥35 to <50 years273030
≥50 to <65 years5413269
≥65 to <80 years4815164
≥80 years1001
Sex: Female, Male
Sex: Female, Male(Participants)Overall BRCAmHRRm^Unassigned (Not BRCAm, Not HRRm^)Total
Female145333181
Male0000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Overall BRCAmHRRm^Unassigned (Not BRCAm, Not HRRm^)Total
Hispanic or Latino3104
Not Hispanic or Latino142313176
Unknown or Not Reported0101
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Overall BRCAmHRRm^Unassigned (Not BRCAm, Not HRRm^)Total
White142313176
Asian2103
Other1001
Unknown or Not Reported0101
08

Study locations

58 sites
  • Research Site
    Plovdiv, 4000, Bulgaria
  • Research Site
    Plovdiv, 4004, Bulgaria
  • Research Site
    Sofia, 1303, Bulgaria
  • Research Site
    Sofia, 1330, Bulgaria
  • Research Site
    Sofia, 1407, Bulgaria
  • Research Site
    Sofia, 1756, Bulgaria
  • Research Site
    Varna, 9010, Bulgaria
  • Research Site
    Calgary, Alberta T2N 4N2, Canada
  • Research Site
    Halifax, Nova Scotia B3H 2E2, Canada
  • Research Site
    London, Ontario N6A 4L6, Canada
  • Research Site
    Toronto, Ontario M5G 1X6, Canada
  • Research Site
    Montreal, Quebec H2X 0A9, Canada
  • Research Site
    Montreal, Quebec H3T 1E2, Canada
  • Research Site
    Brno, 625 00, Czechia
  • Research Site
    Brno, 656 53, Czechia
  • Research Site
    Novy Jicin, 741 01, Czechia
  • Research Site
    Olomouc, 775 20, Czechia
  • Research Site
    Ostrava, 708 52, Czechia
  • Research Site
    Praha 2, 128 08, Czechia
  • Research Site
    Praha 5, 15000, Czechia
  • Research Site
    Budapest, 1032, Hungary
  • Research Site
    Budapest, 1062, Hungary
  • Research Site
    Budapest, 1122, Hungary
  • Research Site
    Debrecen, 4032, Hungary
  • Research Site
    Kecskemét, 6000, Hungary
  • Research Site
    Nyíregyháza, 4400, Hungary
  • Research Site
    Bari, 70124, Italy
  • Research Site
    Milano, 20141, Italy
  • Research Site
    Napoli, 80131, Italy
  • Research Site
    Perugia, 06132, Italy
  • Research Site
    Bialystok, 15-027, Poland
  • Research Site
    Gdansk, 80-402, Poland
  • Research Site
    Kielce, 25-734, Poland
  • Research Site
    Poznan, 60-569, Poland
  • Research Site
    Poznań, Poland
  • Research Site
    Badalona, 08916, Spain
  • Research Site
    Barcelona, 08025, Spain
  • Research Site
    Burgos, 09006, Spain
  • Research Site
    L'Hospitalet de Llobregat, 08908, Spain
  • Research Site
    Madrid, 28040, Spain
  • Research Site
    Madrid, 28041, Spain
  • Research Site
    San Cristobal de La Laguna, 38320, Spain
  • Research Site
    Sevilla, 41009, Spain
  • Research Site
    Valencia, 46010, Spain
  • Research Site
    Valencia, 46026, Spain
  • Research Site
    Zaragoza, 50009, Spain
  • Research Site
    Belfast, BT9 7AB, United Kingdom
  • Research Site
    Birmingham, B18 7QH, United Kingdom
  • Research Site
    Cardiff, CF14 2TL, United Kingdom
  • Research Site
    Glasgow, G12 OYN, United Kingdom
  • Research Site
    Leeds, LS9 7TF, United Kingdom
  • Research Site
    London, SE1 9RT, United Kingdom
  • Research Site
    Manchester, M20 4BX, United Kingdom
  • Research Site
    Newcastle upon Tyne, NE7 7DN, United Kingdom
  • Research Site
    Oxford, OX3 7LJ, United Kingdom
  • Research Site
    Swansea, SA2 8QA, United Kingdom
  • Research Site
    Taunton, TA1 5DA, United Kingdom
  • Research Site
    Wirral, CH63 4JY, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2015 to primary completion in Apr 2020, 54 months.

Results were first posted in Jun 2021, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 10, 2015
First posted
Jun 22, 2015
StartActual
Sep 28, 2015
Primary completionActual
Apr 17, 2020
CompletionActual
Dec 17, 2021
Results first posted
Jun 18, 2021
Last update
Sep 10, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 10, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02476968
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Jun 22, 2015
Start date
Sep 28, 2015
Primary completion
Apr 17, 2020
Completion
Dec 17, 2021
Results posted
Jun 18, 2021
Last update
Sep 10, 2022

Study contacts

Sandro Pignata, Doctor of Medicine
principal investigator · Istituto Nazionale Tumori Fondazione G. Pascale, 80131, Napoli, Italy

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Olaparib

Start the discussion